Introduction Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease oc curring in about 1 in 500 people in the general population. In a majority of cases HCM is caused by mutations in genes encoding sarcomere pro teins. The disease leads to disarray of cardio myocytes with secondary interstitial fibrosis, resulting in myocardial hypertrophy with dia stolic and systolic dysfunctions.
1
B type natriuretic peptide (BNP) is a poly peptide secreted by the ventricular muscle in response to excessive stretching of cardiomy ocytes. Its levels are elevated in patients with heart failure, including those with left ventric ular outflow tract obstruction at rest or diastol ic dysfunction.
2 BNP or N terminal fragment of pro BNP (NT proBNP) levels are elevated in pa tients with HCM also due to silent myocardial ischemia or an end stage form of HCM repre sented by systolic heart failure. 3 The levels of these peptides correlate with functional class assessed according to the New York Heart As sociation (NYHA) classification.
4
Both BNP and NT proBNP are clinically im portant diagnostic and prognostic markers of ischemic heart disease and heart failure, but the usefulness of these biomarkers for risk strat ification in HCM is unclear. The present investi gation was set to determine the prognostic util ity of NT proBNP in patients with HCM. heart failure followed by an unplanned hospi talization (P = 0.003). NT proBNP levels below the cutoff point for the detection of heart failure (<125 pg/ml) were found in 84 patients (14% of the whole group). Mean (SD) age in this group of patients was 31 (11) years. Among those patients there was only a single hos pitalization due to exacerbation of heart failure. All of these patients were initially in NYHA class I or II.
S H O R T C O M M U N I C A T I O N
We demonstrated that NT proBNP is an in dependent predictor of worse clinical outcome in patients with HCM. These results are in line with a previous large prospective study including 847 HCM patients. 4 Another retrospective anal ysis on 772 patients showed that higher levels of BNP correlate with all cause mortality. 5 Both BNP and NT proBNP were found to be markers of worse prognosis in few previously published small studies. 6-10 Our study strongly supports previous findings.
We demonstrated that patients with HCM who were in the lowest tertile of NT proBNP concen trations, and particularly those with biomarker levels below the cutoff point for heart failure de tection (<125 pg/ml), have generally good prog nosis, as demonstrated by lack of deaths or heart transplantations as well as by a small number of unscheduled hospitalizations in this group of patients. Furthermore, the baseline NYHA class in this group of patients with HCM was also lower than in patients in the higher tertiles of NTproBNP concentrations. Therefore, these patients can be considered as a low risk group, provided they are thoroughly screened for the in creased risk of SCD and receive an ICD if neces sary (we reported 2 appropriate device interven tions in this group of patients).
Our study has some limitations. First of all, the results are based on a single NT proBNP mea surement. However, other studies in that area also did not use repetitive biomarker sampling. Secondly, the primary endpoint occurred in a rel atively small number of patients. This was main ly influenced by 2 facts: the relatively short pe riod of follow up and a high frequency of prior ICD implantations in the study group. The de vice was present at baseline in 28% of patients in our group and only in 12% of patients in a pre viously reported large study.
4
We found that the NT proBNP concentra tion is not a predictor of SCD or appropriate ICD interventions. These data suggest that this biomarker cannot be considered a useful risk factor for better identification of high risk pa tients who may benefit from ICD implantation in the primary prevention of SCD.
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Patients in the higher tertiles of NT proBNP concentrations had a higher risk of death or heart transplantation (hazard ratio [HR], 5.9; 95% CI, 2.05-17.04; P = 0.001) and unscheduled hospitalizations due to heart failure (HR, 1.76; 95% CI, 1.03-3.0, P = 0.037) as determined by the multivariable Cox model. Sudden cardiac death or appropriate ICD intervention was not significantly associated with higher levels of NT proBNP. There were no primary events and only a few appropriate ICD interventions in those in the lowest tertile of NT proBNP levels.
Patients with NT proBNP in the second and third tertiles had worse survival rates in com parison to those in the first tertile of the NT proBNP concentrations (P = 0.007) (FIGURE 1). They also had an increased risk of deterioration of 
